Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Credit cards News Centre About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 134.20 1.40
Jaiprak 127.55 0.91
Tata Ste 533.45 0.07
Dlf Ltd 306.75 1.51
Bharti T 313.80 1.78
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Ajanta Pharma Limited
Ajanta Pharma Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532331NSE:AJANTPHARMBloomberg:AJP@INReuters:AJPH.BO
Market Lot: 1Face Value: 10ISIN Demat: INE031B01015
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
27-FEB-08 Ajanta Pharma is planning to invest Rs 600 million to expand its research and development division and manufacturing facilities. The manufacturing capacity at Paithan in Maharashtra will be doubled at a cost of Rs 350 million. The research and development facility will be upgraded at a cost of Rs 250 million by mid 2008. The company has also set up manufacturing facilities in Mauritius and Turkmenistan. ...   More..
Business Profile Future Plans
CEO Talk
Ajanta Pharma is a typical niche player. The companys managing director Purushottam Agrawal is confident of Ajanta Pharma logging in a growth of at least 15 per cent in its topline and much higher than that in its bottomline.   Purushottam Agrawal
One To One
Recent news
Latest News
Care reaffirms `A` rating of Ajanta Pharma   -IRIS 07-Oct-09
Previous

More


Brief Financials (in Rs. Mn.) 
Period ending (months)31-Dec-2009(9)31-Mar-2009 (12)31-Mar-2008 (12)
Net sales 2737.823194.772851.30
Other Income6.4113.767.71
Total Income2744.233208.532859.01
Cost of goods sold2234.842597.332391.98
OPBDIT509.39611.20467.03
PAT184.97213.77177.93
Gross Block---
Equity capital117.96117.96117.96
EPS (Rs.)-18.2615.20
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-2.66 - 6.384.29 - 8.54
Debt / Equity (x)---
Operating margin (% of OI)18.619.016.3
Net margin (% of OI) 6.7 6.7 6.2
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Ajanta House
Charkop
Kandivli (West)
Mumbai
Maharashtra-400 067
PHONE
(022) 6606 1000
FAX
(022) 6606 1200/ 1300
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Credit cards | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris
© All rights reserved. IRIS Business Services Private Limited
Disclaimer